Skip header and navigation

Refine By

15 records – page 1 of 2.

[A comparative study of the hemodynamic and antioxidant effects of Capoten and prazosin in patients with refractory heart failure]

https://arctichealth.org/en/permalink/ahliterature54537
Source
Lik Sprava. 1997 Mar-Apr;(2):72-6
Publication Type
Article
Author
R O Sabadyshyn
B I Rudyk
N H Blinova
O Ia Slipak
Source
Lik Sprava. 1997 Mar-Apr;(2):72-6
Language
Ukrainian
Publication Type
Article
Keywords
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Antioxidants - therapeutic use
Captopril - therapeutic use
Cardiomyopathy, Dilated - complications - drug therapy - physiopathology
Comparative Study
Drug Evaluation
English Abstract
Female
Heart Failure, Congestive - drug therapy - etiology - physiopathology
Hemodynamic Processes - drug effects
Humans
Hypertension - complications - drug therapy - physiopathology
Lipid Peroxidation - drug effects
Male
Middle Aged
Myocardial Ischemia - complications - drug therapy - physiopathology
Prazosin - therapeutic use
Abstract
Overall fifty one patients with chronic cardiac insufficiency (ChCI) were studied for changes in parameters characterizing hemodynamics and lipid peroxidation (LPO) under treatment with kapoten and prazosin. Kapoten was found to be capable of exerting an antioxidant effect and working in ways beneficial for the pulmonary circulation, while prazosin is generally indicated to patients with ChCI presenting with increased end diastolic pressure in the left ventricle. Prazosin activates LPO, for which reason its pro-oxidant action needs to be drug-corrected. Because of marked pharmacologic effects of both drugs in dealing with refractory circulatory insufficiency it is advisable that further studies be made in order that we might be able to determine indications for kapoten and prazosin therapy in coronary patients as well as those with arterial hypertension, cardiomyopathies, valvular defects, ChCI with complications more accurately.
PubMed ID
9333490 View in PubMed
Less detail

The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group.

https://arctichealth.org/en/permalink/ahliterature48697
Source
J Hypertens. 1990 Nov;8(11):985-90
Publication Type
Article
Date
Nov-1990
Source
J Hypertens. 1990 Nov;8(11):985-90
Date
Nov-1990
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Adult
Aged
Captopril - therapeutic use
Cardiovascular Diseases - mortality
Diuretics - therapeutic use
Female
Humans
Hypertension - prevention & control
Male
Middle Aged
Prospective Studies
Survival Rate
Sweden
Abstract
The Captopril Prevention Project (CAPPP) is a prospective, randomized, multi-centre intervention trial designed to investigate whether antihypertensive treatment with the angiotensin converting enzyme (ACE) inhibitor captopril may reduce cardiovascular mortality and morbidity more than a therapeutic regimen which does not include an ACE inhibitor. Secondary objectives are to compare total mortality, the development or deterioration of ischaemic heart disease, left ventricular failure, atrial fibrillation, diabetes mellitus and possible differences in renal function in the two groups. Male and female patients with essential hypertension, aged 25-66 years, will be randomly allocated to antihypertensive treatment which will comprise either the use of the ACE inhibitor captopril or will exclude all types of ACE inhibitors. Some 275 hypertension centres and health care centres in Sweden and Finland will take part in this multi-centre trial. A total of 7000 patients will be recruited and studied for an average period of 5 years, the assumption being that a 20% difference in cardiovascular mortality between the two groups can be detected with a power of 80% at the 5% significance level (two-sided test).
PubMed ID
1981218 View in PubMed
Less detail

The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status.

https://arctichealth.org/en/permalink/ahliterature54424
Source
Blood Press. 1997 Nov;6(6):365-7
Publication Type
Article
Date
Nov-1997
Author
L. Hansson
T. Hedner
L. Lindholm
A. Niklason
K. Luomanmäki
L. Niskanen
J. Lanke
B. Dahlöf
U. de Faire
C. Mörlin
B E Karlberg
P O Wester
J E Björck
Source
Blood Press. 1997 Nov;6(6):365-7
Date
Nov-1997
Language
English
Publication Type
Article
Keywords
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Blood Pressure - drug effects - physiology
Captopril - therapeutic use
Data Interpretation, Statistical
Female
Finland - epidemiology
Genes - genetics
Glucose Clamp Technique
Humans
Hypertension - drug therapy - epidemiology - prevention & control
Insulin - blood
Lipoproteins - blood - drug effects
Male
Middle Aged
Myocardial Infarction - genetics
Peptidyl-Dipeptidase A - genetics
Polymorphism, Genetic
Prospective Studies
Sweden - epidemiology
Abstract
The Captopril Prevention Project (CAPPP) is an ongoing intervention study conducted in 11,019 hypertensive patients in Sweden and Finland. Patients have been randomized to receive either conventional antihypertensive therapy (diuretics and/or beta-blockers) or captopril-based treatment. A prospective, randomized, open, blinded-endpoint evaluation (PROBE) study design is used to compare these two therapeutic regimens as regards cardiovascular morbidity and mortality. The rationale for the CAPPP Study are the many observations of beneficial effects of ACE inhibition, as compared to diuretics and beta-blockers, on intermediary endpoints such as insulin sensitivity, serum lipoproteins, left ventricular hypertrophy and renal function. Captopril has also been shown to be markedly effective in the treatment of left ventricular dysfunction as well as congestive heart failure. The hypothesis is that these differences might result in improved risk reduction when ACE inhibitors are used in the treatment of hypertension. The present paper describes the baseline data and the changes in blood pressure during the first year in the total cohort. During the first year the average blood pressure was reduced by 11/8 mm Hg. A number of substudies have been conducted in the CAPPP Study. In one of these insulin sensitivity was compared in a subgroup of the patients using the euglycemic insulin clamp technique. In another substudy the ACE gene was sequenced and some new polymorphisms were discovered. Several other substudies are in progress or in the planning phase. The main results of the CAPPP Study should be available by mid-1998. Some of the intended anayses of the final results as well as other planned substudies are briefly described here.
PubMed ID
9495662 View in PubMed
Less detail

A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators.

https://arctichealth.org/en/permalink/ahliterature221438
Source
N Engl J Med. 1993 Mar 18;328(11):779-84
Publication Type
Article
Date
Mar-18-1993
Author
J L Rouleau
L A Moyé
M A Pfeffer
J M Arnold
V. Bernstein
T E Cuddy
G R Dagenais
E M Geltman
S. Goldman
D. Gordon
Author Affiliation
Université de Sherbrooke, Que., Canada.
Source
N Engl J Med. 1993 Mar 18;328(11):779-84
Date
Mar-18-1993
Language
English
Publication Type
Article
Keywords
Angina Pectoris - epidemiology
Canada
Captopril - therapeutic use
Coronary Angiography - utilization
Coronary Care Units - utilization
Follow-Up Studies
Humans
Myocardial Infarction - mortality - therapy
Myocardial Revascularization - utilization
Physician's Practice Patterns - statistics & numerical data
Quality of Health Care
Random Allocation
Recurrence
Treatment Outcome
United States
Abstract
There are major differences in the organization of the health care systems in Canada and the United States. We hypothesized that these differences may be accompanied by differences in patient care.
To test our hypothesis, we compared the treatment patterns for patients with acute myocardial infarction in 19 Canadian and 93 United States hospitals participating in the Survival and Ventricular Enlargement (SAVE) study, which tested the effectiveness of captopril in this population of patients after a myocardial infarction.
In Canada, 51 percent of the patients admitted to a participating coronary care unit had acute myocardial infarctions, as compared with only 35 percent in the United States (P
Notes
Comment In: N Engl J Med. 1993 Mar 18;328(11):805-78437602
Comment In: N Engl J Med. 1993 Sep 23;329(13):964; author reply 965-68361514
Comment In: N Engl J Med. 1993 Sep 23;329(13):964-5; author reply 965-68123103
Comment In: N Engl J Med. 1993 Sep 23;329(13):965; author reply 965-68361516
PubMed ID
8123063 View in PubMed
Less detail

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

https://arctichealth.org/en/permalink/ahliterature52975
Source
Lancet. 1999 Feb 20;353(9153):611-6
Publication Type
Article
Date
Feb-20-1999
Author
L. Hansson
L H Lindholm
L. Niskanen
J. Lanke
T. Hedner
A. Niklason
K. Luomanmäki
B. Dahlöf
U. de Faire
C. Mörlin
B E Karlberg
P O Wester
J E Björck
Author Affiliation
Department of Public Health and Social Sciences, University of Uppsala, Sweden.
Source
Lancet. 1999 Feb 20;353(9153):611-6
Date
Feb-20-1999
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Captopril - therapeutic use
Cause of Death
Cerebrovascular Disorders - etiology - prevention & control
Comparative Study
Confidence Intervals
Diuretics - therapeutic use
Female
Follow-Up Studies
Heart Diseases - etiology - prevention & control
Humans
Hypertension - drug therapy
Intervention Studies
Male
Middle Aged
Myocardial Infarction - etiology - prevention & control
Prospective Studies
Research Support, Non-U.S. Gov't
Risk factors
Survival Rate
Abstract
BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitors have been used for more than a decade to treat high blood pressure, despite the lack of data from randomised intervention trials to show that such treatment affects cardiovascular morbidity and mortality. The Captopril Prevention Project (CAPPP) is a randomised intervention trial to compare the effects of ACE inhibition and conventional therapy on cardiovascular morbidity and mortality in patients with hypertension. METHODS: CAPPP was a prospective, randomised, open trial with blinded endpoint evaluation. 10,985 patients were enrolled at 536 health centres in Sweden and Finland. Patients aged 25-66 years with a measured diastolic blood pressure of 100 mm Hg or more on two occasions were randomly assigned captopril or conventional antihypertensive treatment (diuretics, beta-blockers). Analysis was by intention-to-treat. The primary endpoint was a composite of fatal and non-fatal myocardial infarction, stroke, and other cardiovascular deaths. FINDINGS: Of 5492 patients assigned captopril and 5493 assigned conventional therapy, 14 and 13, respectively, were lost to follow-up. Primary endpoint events occurred in 363 patients in the captopril group (11.1 per 1000 patient-years) and 335 in the conventional-treatment group (10.2 per 1000 patient-years; relative risk 1.05 [95% CI 0.90-1.22], p=0-52). Cardiovascular mortality was lower with captopril than with conventional treatment (76 vs 95 events; relative risk 0.77 [0.57-1-04], p=0.092), the rate of fatal and non-fatal myocardial infarction was similar (162 vs 161), but fatal and non-fatal stroke was more common with captopril (189 vs 148; 1.25 [1-01-1-55]. p=0.044). INTERPRETATION: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality. The difference in stroke risk is probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Notes
Comment In: ACP J Club. 1999 Jul-Aug;131(1):18
Comment In: Lancet. 1999 Feb 20;353(9153):604-510030320
Comment In: Lancet. 1999 Jul 3;354(9172):7310406390
Comment In: Lancet. 2000 Apr 1;355(9210):1181-2; author reply 1183-410791398
Comment In: Lancet. 2000 Apr 1;355(9210):1183; author reply 1183-410791401
Comment In: Lancet. 2000 Dec 2;356(9245):1927; author reply 1928-911130405
Comment In: Lancet. 2000 Dec 2;356(9245):1929-3011130406
Comment In: Lancet. 2000 Feb 19;355(9204):652; author reply 65310697002
Comment In: Lancet. 2001 Dec 8;358(9297):1995-611747948
PubMed ID
10030325 View in PubMed
Less detail

[Effects of angiotensin-converting enzyme (ACE) inhibitors on water-salt homeostasis in hypertensive patients living in Far North].

https://arctichealth.org/en/permalink/ahliterature198729
Source
Klin Med (Mosk). 2000;78(3):42-6
Publication Type
Article
Date
2000
Author
A M Vershinina
L I Gapon
I F Bazhukhina
D V Teffenberg
V V Drozdov
N A Spitsina
O I Sergeichik
Source
Klin Med (Mosk). 2000;78(3):42-6
Date
2000
Language
Russian
Publication Type
Article
Keywords
Adult
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological Markers - urine
Captopril - therapeutic use
Cold Climate
Environmental Exposure
Homeostasis - drug effects
Humans
Hypertension - drug therapy - metabolism
Male
Prognosis
Ramipril - therapeutic use
Siberia
Sodium - urine
Water-Electrolyte Balance - drug effects
Abstract
The aim of the study was evaluation of ACE inhibitors (captopril and ramipril) effect on water-salt homeostasis in the treatment of patients with arterial hypertension (AH) living in the Far North of Russia. 100 male patients with mild and moderate AH were examined 2 weeks, 3 and 6 months after administration of captopril or ramipril. The drugs are shown to correct water-salt metabolism. This is explained by better renal function due to speeding up glomerular filtration and increased sodium excretion with urine, and by activity of humoral mechanisms (inhibited activity of plasma renin, low plasma concentration of aldosterone and its 24-h excretion). Comparison of captopril versus ramipril demonstrates advantages of prolonged ramipril in respect to regulation of water salt metabolism in the treatment of essential hypertension in the Far North.
PubMed ID
10790965 View in PubMed
Less detail

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.

https://arctichealth.org/en/permalink/ahliterature217429
Source
J Am Coll Cardiol. 1994 Sep;24(3):583-91
Publication Type
Article
Date
Sep-1994
Author
J L Rouleau
M. Packer
L. Moyé
J. de Champlain
D. Bichet
M. Klein
J R Rouleau
B. Sussex
J M Arnold
F. Sestier
Author Affiliation
Montreal Heart Institute, Quebec, Canada.
Source
J Am Coll Cardiol. 1994 Sep;24(3):583-91
Date
Sep-1994
Language
English
Publication Type
Article
Keywords
Aged
Aldosterone - blood
Analysis of Variance
Arginine Vasopressin - blood
Atrial Natriuretic Factor - blood
Canada
Captopril - therapeutic use
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood - drug therapy - mortality
Neurotransmitter Agents - blood
Norepinephrine - blood
Prognosis
Proportional Hazards Models
Renin - blood
Abstract
This study attempted to evaluate whether neurohumoral activation at the time of hospital discharge in postinfarction patients helps to predict long-term prognosis and whether long-term therapy with the angiotensin-converting enzyme inhibitor captopril modifies this relation.
Neurohumoral activation persists at the time of hospital discharge in a large number of postinfarction patients. The Survival and Ventricular Enlargement (SAVE) study demonstrated that the angiotensin-converting enzyme inhibitor captopril improves survival and decreases the development of severe heart failure in patients with left ventricular dysfunction (left ventricular ejection fraction
PubMed ID
7915733 View in PubMed
Less detail

Recent intervention trials in hypertension initiated in Sweden--HOT, CAPPP and others. Hypertension Optimal Treatment Study. Captopril Prevention Project.

https://arctichealth.org/en/permalink/ahliterature201340
Source
Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):507-15
Publication Type
Article
Author
L. Hansson
Author Affiliation
Department of PublicHealth and Social Sciences: Geriatrics, University of Uppsala, Sweden.
Source
Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):507-15
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Adult
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Aspirin - therapeutic use
Blood pressure
Calcium Channel Blockers - therapeutic use
Captopril - therapeutic use
Cardiovascular Diseases - mortality - prevention & control
Clinical Trials as Topic
Felodipine - therapeutic use
Female
Humans
Hypertension - drug therapy
Isradipine - therapeutic use
Male
Middle Aged
Randomized Controlled Trials as Topic
Stroke - prevention & control
Sweden
Abstract
In 1998 the final results were presented of two large intervention trials in hypertension, the Hypertension Optimal Treatment Study (HOT) and the Captopril Prevention Project (CAPPP). Both were initiated from Sweden although the HOT Study was conducted in 26 countries worldwide and the CAPPP Study in Finland and Sweden. The HOT and CAPPP trials and their principal results will be reviewed briefly here. In addition a brief up-date will be provided of three ongoing intervention trials in hypertension that were also initiated from Sweden: the Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-), the Nordic Diltiazem (NORDIL) Study and the Study on Cognition and Prognosis in Elderly Hypertensives (SCOPE).
PubMed ID
10423077 View in PubMed
Less detail

15 records – page 1 of 2.